Skip to main content
micro-community-banner
 
  • Saved


Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases - PubMed

Immune checkpoint inhibitors (ICIs) have resulted in improved outcomes in non-small cell lung cancer (NSCLC) patients. However, data demonstrating the efficacy of ICIs in NSCLC brain metastases (NSCLCBM) is limited. ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34518623/

Show More Comments

  • 4 days 22 hours
    Key Points • Conclusion/Relevance: “This study reports a significant survival benefit of ICIs over chemotherapy or local control alone in patients with NSCLCBM [NSCLC brain metastases]. This retrospective analysis of patients treated Show More
  • Saved

made a Post


Characterization of KRAS Mutation Subtypes in Non-Small Cell Lung Cancer - PubMed

KRAS is the most commonly mutated oncogene in NSCLC and development of direct KRAS inhibitors has renewed interest in this molecular variant. Different KRAS mutations may represent a unique biologic ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34518295/

  • Saved

made a Post

Targeting mutated GTPase KRAS in tumor therapies - PubMed

Kirsten rat sarcoma virus oncogene (KRAS) mutation accounts for approximately 85% of RAS-driven cancers, and participates in multiple signaling pathways and mediates cell proliferation, differentiation and metabolism. KRAS has been ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34520956/

  • Saved

Sensitive cell-free tumor DNA analysis in supernatant pleural effusions supports therapy selection and disease monitoring of lung cancer patients - PubMed

Supernatant pleural effusions (PE) have shown to be a valuable source for the detection of driver mutations in circulating tumor DNA (ctDNA). In this prospective study, the clinical value of ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34481168/

Show More Comments

  • 1 week 4 days
    Key Points • Conclusion/Relevance: “Together, this is the first study showing that ctDNA analysis on supernatant PE could be used for therapy response monitoring. Due to a higher ctDNA concentration and fractional Show More
  • Saved

made a Post

Oncofetal Chondroitin Sulfate Is a Highly Expressed Therapeutic Target in Non-Small Cell Lung Cancer - PubMed

Broad-spectrum therapeutics in non-small cell lung cancer (NSCLC) are in demand. Most human solid tumors express proteoglycans modified with distinct oncofetal chondroitin sulfate (CS) chains that can be detected and ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34503301/

  • Saved

made a Post

The Prognostic Effect of KRAS Mutations in Non-Small Cell Lung Carcinoma Revisited: A Norwegian Multicentre Study - PubMed

1 Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Technology and Science, N-7491 Trondheim, Norway. 2 Department of Pathology, St. Olav's Hospital, Trondheim University Hospital, N-7006 Trondheim, Norway. ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34503114/

  • Saved

made a Post

Perspectives and Issues in the Assessment of SMARCA4 Deficiency in the Management of Lung Cancer Patients - PubMed

Lung cancers are ranked third among the cancer incidence in France in the year 2020, with adenocarcinomas being the commonest sub-type out of ~85% of non-small cell lung carcinomas. The ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34440689/

  • Saved

made a Post

The KRAS-G12C inhibitor: activity and resistance - PubMed

Although it has long been deemed "undruggable", with the development of drugs specifically binding the KRAS-G12C mutant protein, clinical trials that directly inhibit oncogenic RAS have recently made promising improvements. ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34471232/

  • Saved

made a Post

The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC) - PubMed

doi: 10.1016/j.lungcan.2021.08.005. Online ahead of print. 1 Queensland University of Technology, Centre for Genomics and Personalised Health, School of Biomedical Sciences, Brisbane, Australia; Translational Research Institute, Brisbane, Australia; Institute for ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34455214/

  • Saved

from Pathologist Connect made a Post

New study helps point the way toward developing personalized treatments distinct from those used for smokers’ cancers.

Study: Never-smokers' lung cancers genetically differ from smokers' tumors

esearchers have identified unique genetic signatures of lung cancer in people who never smoked cigarettes, using whole genome sequencing to analyze tumors from this under-studied population. The new study, published ..... see more

Source : https://www.statnews.com/2021/09/06/never-smokers-lung-cancers-genetically-different-from-smokers-tumors/

  • Saved

from Pathologist Connect made a Post

Treating lung cancer is more precise than ever, thanks to biomarker testing, which gives clinicians a better understanding of individual’s tumors.

Biomarker Testing in Lung Cancer Continues to Improve Outcomes, Move the Field Forward

Years ago, many patients with lung cancer were treated the same, as there was limited knowledge about the disease and limited therapies to treat it. Then, biomarker testing brought precision ..... see more

Source : https://www.curetoday.com/view/biomarker-testing-in-lung-cancer-continues-to-improve-outcomes-move-the-field-forward

On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma - PubMed

Non-small cell lung carcinoma (NSCLC) is a leading cause of cancer death. Approximately one-third of patients with NSCLC have a KRAS mutation. KRAS G12C , the most common mutation, is ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34417059/

Show More Comments

  • Saved

made a Post

Transition From Distinct Types of KRAS Mutation-Harboring Multifocal Lung Adenocarcinoma to Rhabdoid Tumor: A Longitudinal Follow-Up - PubMed

BACKGROUND Rhabdoid tumor (RT) of the lung is a rare and aggressive malignancy. The origin of and the mutation responsible for RT are entirely unknown. The distinction between RT associated ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34432771/

  • Saved

made a Post

Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma - PubMed

1 Department of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China. 2 Department of Respiratory Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine at Bingjiang, Hangzhou, ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34430361/

  • Saved

from Pathologist Connect made a Post

a group of researchers from Memorial Sloan Kettering Cancer Center reported in the journal Science Translational Medicine that a specific pattern, or “signature,” of markers on immune cells in the blood is a likely biomarker of response to checkpoint immunotherapy. Within this immune signature, a molecule LAG-3 provided key information...

MSK Study Identifies Biomarker That May Help Predict Benefits of Immunotherapy

In recent years, immune-based treatments for cancer have buoyed the hopes of doctors and patients alike. Drugs called immune checkpoint inhibitors have provided lifesaving benefits to a growing list of ..... see more

Source : https://www.mskcc.org/news/msk-study-identifies-biomarker-may-help-predict-benefits-immunotherapy

  • Saved

made a Post

KRAS-targeted therapies in advanced solid cancers: drug the undruggable? - PubMed

1 Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, 94800, France. 2 Department of Pathology, National Institute of Pathology, Baabda, 1003, Lebanon. 3 Department of Radiation Oncology, Hotel-Dieu de France ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34148378/

  • Saved

made a Post

Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics - PubMed

Introduction: KRAS is the most frequently mutated oncogenic driver in pancreatic, lung, and colon cancer. Recently, KRAS inhibitors in clinical use show promising activity but most responses are partial and ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34347509/

  • Saved

made a Post

KRAS inhibitor-resistance in MET-amplified KRAS G12C non-small cell lung cancer induced by RAS- and non-RAS-mediated cell signaling mechanisms - PubMed

doi: 10.1158/1078-0432.CCR-21-0856. Online ahead of print. 1 Department of Medical Oncology, Kindai University Faculty of Medicine. 2 Department of Medical Oncology, Kindai University Faculty of Medicine [email protected] 3 Division of ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34365406/

  • Saved

from Pathologist Connect made a Post

J&J partners with AI startup to identify early lung cancer cases

J&J partners with AI startup to identify early lung cancer cases

A Johnson & Johnson division focused on developing tools to combat lung cancer is partnering with a clinical decision-support startup that recently achieved regulatory clearance for an early detection tool, ..... see more

Source : https://www.modernhealthcare.com/information-technology/jj-partners-ai-startup-identify-early-lung-cancer-cases

  • Saved

made a Post

KRAS inhibitor-resistance in MET-amplified KRAS G12C non-small cell lung cancer induced by RAS- and non-RAS-mediated cell signaling mechanisms - PubMed

doi: 10.1158/1078-0432.CCR-21-0856. Online ahead of print. 1 Department of Medical Oncology, Kindai University Faculty of Medicine. 2 Department of Medical Oncology, Kindai University Faculty of Medicine [email protected] 3 Division of ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34365406/